Literature DB >> 8388977

Chronic exposure to morphine and naltrexone induces changes in catecholaminergic neurotransmission in rat brain without altering mu-opioid receptor sensitivity.

T J De Vries1, G H Tjon Tien Ril, J W Van der Laan, A H Mulder, A N Schoffelmeer.   

Abstract

In order to investigate the role of mu-opioid receptor regulation in catecholaminergic neurotransmission during morphine tolerance/dependence and supersensitivity, we measured changes in number and functional properties of two distinct types of mu receptors in the brain of rats chronically treated with morphine and naltrexone. In membranes of striatum and cortex of morphine treated rats the binding of mu ligand [3H]DAMGO was unaltered, whereas an increase in mu binding sites was found in these brain regions of naltrexone treated rats. The ability of the mu agonist DAMGO to inhibit the dopamine D-1 receptor stimulated cAMP production in striatal slices and the electrically evoked release of [3H]noradrenaline from cortical slices was unaffected in both experimental groups. The major changes found were an increased D-1 receptor stimulated cAMP production and an enhanced release of noradrenaline in morphine treated rats and a decreased D-1 receptor stimulated cAMP production in naltrexone treated rats. These data support the hypothesis that tolerance and supersensitivity to morphine and other mu-opioids may be caused by up- and down-regulated neuronal second messenger systems linked to mu-opioid receptors, rather than by changes in the sensitivity of the mu-opioid receptor itself.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388977     DOI: 10.1016/0024-3205(93)90476-j

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Effects of chronic treatment with methadone and naltrexone on sleep in addicts.

Authors:  J Staedt; F Wassmuth; G Stoppe; G Hajak; A Rodenbeck; W Poser; E Rüther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 2.  Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities.

Authors:  Jean C Dinh; Chelsea M Hosey-Cojocari; Bridgette L Jones
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

3.  Regulation of rat MOR-1 gene expression after chronic intracerebroventricular administration of morphine.

Authors:  Zhi-Ping Zhu; Ramesh B Badisa; Donald E Palm; Carl B Goodman
Journal:  Mol Med Rep       Date:  2011-11-15       Impact factor: 2.952

4.  Opposing role of dopamine D1 and D2 receptors in modulation of rat nucleus accumbens noradrenaline release.

Authors:  L J Vanderschuren; G Wardeh; T J De Vries; A H Mulder; A N Schoffelmeer
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

5.  Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment.

Authors:  F Noble; B M Cox
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

6.  Dopamine D₄ receptor counteracts morphine-induced changes in µ opioid receptor signaling in the striosomes of the rat caudate putamen.

Authors:  Diana Suárez-Boomgaard; Belén Gago; Alejandra Valderrama-Carvajal; Ruth Roales-Buján; Kathleen Van Craenenbroeck; Jolien Duchou; Dasiel O Borroto-Escuela; José Medina-Luque; Adelaida de la Calle; Kjell Fuxe; Alicia Rivera
Journal:  Int J Mol Sci       Date:  2014-01-21       Impact factor: 5.923

7.  Heterodimerization of Mu Opioid Receptor Protomer with Dopamine D2 Receptor Modulates Agonist-Induced Internalization of Mu Opioid Receptor.

Authors:  Lakshmi Vasudevan; Dasiel O Borroto-Escuela; Jelle Huysentruyt; Kjell Fuxe; Deepak K Saini; Christophe Stove
Journal:  Biomolecules       Date:  2019-08-14

8.  Determination of μ-, δ- and κ-opioid receptors in forebrain cortex of rats exposed to morphine for 10 days: Comparison with animals after 20 days of morphine withdrawal.

Authors:  Hana Ujcikova; Martina Hlouskova; Kristina Cechova; Katerina Stolarova; Lenka Roubalova; Petr Svoboda
Journal:  PLoS One       Date:  2017-10-20       Impact factor: 3.240

Review 9.  Endogenous opiates: 1993.

Authors:  G A Olson; R D Olson; A J Kastin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.